MAF-10L 

MAF-10L is a membrane-disrupting agent, a cationic amphipathic Mastoparan AF derivative with enhanced α-helicity. MAF-10L preferentially interacts with DOPS lipids in cancer cell membranes, disrupting cancer cell membranes to trigger membrane leakage. MAF-10L can be used for the research of cancer^[1].

MAF-10L (50 µM) shows the highest α-helical content among tested derivatives, with 48.7% helicity in PBS and 99.7% helicity in 10% SDS^[1].
MAF-10L (50 µM) has the highest self-association propensity in the MAF series^[1].
MAF-10L (0.39-200 µM; 6 h) exhibits potent anticancer activity against 4T1, B16F10, CT26, A549, and Hep3b cells with IC₅₀ values ranging from 2.4 to 9.2 µM^[1].
MAF-10L (4-128 µM; 20 min) exhibits elevated hemolytic activity on RBCs, with higher percentages at increased concentrations^[1].
MAF-10L (5-10 µM; 1 h) damages the plasma membrane of A549 cells, leading to increased PI uptake^[1].
MAF-10L (50 ns) maintains a fully α-helical structure during 50 ns MD simulation in water^[1].
MAF-10L (50 ns) translocates across the cancer cell membrane model with a low energy barrier and minimal lipid disruption, supported by its α-helical structure^[1].
MAF-10L (2 µM; 6 h) triggers hallmarks of immunogenic cell death in cancer cells, including elevated calreticulin expression and ATP release^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1555.00

C₇₆H₁₃₅N₁₉O₁₅

3107186-50-2

Ile-Asn-Leu-Lys-Ala-Ile-Ala-Ala-Leu-Leu-Lys-Lys-Leu-Phe-NH2

INLKAIAALLKKLF-NH2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Bui Thi Phuong H, et al. Developing Potent and Selective Anticancer Therapy through Chemical Approaches and the Combination of Cationic Amphipathic Oncolytic Peptides. J Med Chem. 2025;68(11):11875-11893.  [Content Brief]